The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Shares of Vertex Pharmaceuticals Inc. VRTX slid 0.46% to $408.76 Friday, on what proved to be an all-around rough trading ...

This was the stock's fourth consecutive day of gains.

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA – Research Report), ...

We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The drug candidate is administered through oral route. It acts by targeting APO-L1 function. Vertex Pharmaceuticals (Vertex) is a biotechnology company that discovers, develops and commercializes ...

If you’re on the fence about investing in Vertex Pharmaceuticals Incorporated or AbbVie Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making ...

Vertex Pharmaceuticals (VRTX) closed at $469.29 in the latest trading session, marking a -0.99% move from the prior day. The stock's change was less than the S&P 500's daily loss of 0.3%.

Vertex had developed the candidate as a treatment for rheumatoid arthritis, taking it as far as a midphase trial in the setting. When EIP merged with Diffusion Pharmaceuticals last year to create ...